Investing.com -- BridgeBio Pharma Inc. (NASDAQ:BBIO) reported fourth quarter revenue of $154.2 million, exceeding analyst estimates of $146.16 million, though the company posted a wider-than-expected ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

Dayno emphasized, “Guiding WAKIX to blockbuster status in 2026, extending the WAKIX franchise with pitolisant GR's target PDUFA date in Q1 2027, expanding the pitolisant franchise with the advancement ...

After a triple-overtime goal in game 3 of the semifinals by Raine Bradley against the Algonquin Barons, the Chippewa Ravens ...

The controversy began in September 2024 when Chief Minister N. Chandrababu Naidu alleged that adulterated ghee, laced with ...

The ousted member says this NDA goes beyond legitimately confidential case-specific information and covers board trainings ...

China Medical System Holdings Limited ('CMS” or the 'Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited ('Dermavon”, an innovative pharmaceutical company specialized in skin ...

According to the Minister, the task team comprises veterinarians, scientists, and technicians whose roles are strictly technical.

Operating capital runway sufficient into the fourth quarter of 2026 In-person Type C FDA meeting scheduled by end of the first quarter of 2026 to discuss the latest CNM-Au8 data submitted in late 2025 ...

NEWARK, CA / ACCESS Newswire / February 24, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, w ...